Comparative effectiveness of immunotherapeutic regimens for untreated advanced non-small-cell lung cancer in real-world clinical practice: a Japanese cancer registry cohort study
Our investigation suggested that compared with immunomonotherapy regimens, immunochemotherapy regimens might contribute more to prolonged survival than immunomonotherapy regimens, and that pembrolizumab-containing regimens might be more beneficial for extending prognosis compared with atezolizumab-containing regimens.
Authors
- Tomoaki Tanaka (ORCID: https://orcid.org/0000-0002-6369-5861)
- Takahisa Kawamura (ORCID: https://orcid.org/0000-0001-6611-659X)
- Isao Miyashiro (ORCID: https://orcid.org/0000-0002-2575-4971)
- Kazumi Nishino (ORCID: https://orcid.org/0000-0003-2000-7472)
- Shun Futamura
- Motohiro Tamiya (ORCID: https://orcid.org/0000-0001-6529-3092)
- Akito Miyazaki (ORCID: https://orcid.org/0009-0004-7188-674X)
- Kei Kunimasa (ORCID: https://orcid.org/0000-0002-5241-3486)
- Tomio Inoue (ORCID: https://orcid.org/0000-0001-6848-0491)
- Toshitaka Morishima (ORCID: https://orcid.org/0000-0002-0747-3287)
- K. Komuta
Institutions
- Osaka International Cancer Institute (JP)
Publication Details
- Journal
- ESMO Real World Data and Digital Oncology
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1016/j.esmorw.2025.100137
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00